Form 4: Arcus Biosciences Director Andrew Perlman Reports Stock and Option Grants

Director Andrew Perlman reports receiving stock and option grants from Arcus Biosciences.

Summary

• On June 6, 2024, Andrew Perlman, a director of Arcus Biosciences, reported transactions involving the company's securities.
• Perlman was granted 8,400 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will fully vest upon a change in control of the company.
• Perlman also received an option to buy 24,000 shares of common stock at an exercise price of $15.90.
• This option vests fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will fully vest and become exercisable upon a change in control of the company.
• Following these transactions, Perlman directly owns 29,325 shares of Arcus Biosciences common stock and options to purchase 24,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices, indicating confidence in the company's future.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule tied to the annual meeting or a change in control incentivizes long-term value creation.

Industry Context

This type of equity compensation is standard practice in the biotech industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity grants to directors are a common practice in publicly traded companies, particularly in the biotech sector.
• Companies like Gilead Sciences, Amgen, and Regeneron also use stock options and RSUs as part of their compensation packages for directors and executives.
• The vesting schedules and terms are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• The equity grants align the director's interests with those of shareholders, potentially driving long-term value creation.

Key Dates